China (Mainland)
Sex Enhancement Powder Flibanserin cas:167933-07-5 CAS NO.167933-07-5
- FOB Price: USD: 0.80-1.00 /Gram Get Latest Price
- Min.Order: 10 Gram
- Payment Terms: T/T,MoneyGram,Other
- Available Specifications:
1(10-100)Gram1(100-1000)Gram
- Product Details
Keywords
- Flibanserin
- Flibanserin
- steroid
Quick Details
- ProName: Sex Enhancement Powder Flibanserin cas...
- CasNo: 167933-07-5
- Molecular Formula: C20H21F3N4O
- Appearance: White Or Almost White Crystalline Powd...
- Application: Bulking cycle
- DeliveryTime: 4-7days
- PackAge: 1kg/foil bag or as you requst
- Port: hongkong/hongkong
- ProductionCapacity: 1000 Kilogram/Month
- Purity: 99%
- Transportation: by express
- LimitNum: 10 Gram
- Alias: Flibanserin
- Molecular formula: C20H21F3N4O
- Molecular Weight: 390.40
- Grade: Pharmaceutical Grade
Superiority
Our Advantage:
1. Our company specilize in Pharmaceutical raw materials for more than 13 years, with high quality and competitive price. Our products has good reputation in this field.
2. We have kinds of products in stock, so we can delivery quickly and safety after you payment.
3. Package update will be told ASAP, and we will try best solving when customer encountered various problems.
Welcome to order our product.
Contact info:
vivian@chembj.com
skype:Viviandeng1225
whatsapp:+8615069093656
Details
Flibanserin
Synonyms:3-[2-[4-[4-(Trifluoromethyl)phenyl]piperazin-1-yl]ethyl]-1H-benzimidazol-2-one
CAS NO.:167933-07-5
Molecular Formula:C20H21F3N4O
Molecular Weight:390.40
Purity:99%
Grade:Pharmaceutical Grade
Appearance:White powder
Grade:Pharmaceutical Grade
Product Categories:API
Addyi (flibanserin) is a novel, non-hormonal, multifunctional serotonin agonist antagonist (MSAA) for the treatment of hypoactive sexual desire disorder in premenopausal wome.
Flibanserin, a Medical Treatment for Female Hypoactive Sexual Desire Disorder
Flibanserin ( Addyi ) is a new drug being investigated for the prevention of HSDD in woman. HSDD, is a relatively new term developed to describe Hypoactive Sexual Desire Disorder which basically means a woman whose is otherwise healthy has a lacking libido, or a lack of sexual desire. Studies show that about 10-20% of women face this problem and some say HSDD outnumbers men with sexual problems. Flibanserin is classified as a 5-HT serotonin receptor agonist and a dopamine D4 receptor partial agonist. It is a Non-Hormonal agent that in essence increases dopamine and noradrenalin while reducing Serotonin in the brain. This in return seemingly has a positive effect on a woman's sexual craving who was otherwise lacking in this area. The benefits of it being Non-Hormonal are that it will not have the problems associated with other hormonal treatments such as a negative altered mood among other issues.
Medical uses
Flibanserin is used for hypoactive sexual desire disorder among women. Those receiving flibanserin report a 0.5 increase compared to placebo in the number of times they had “satisfying sexual events”. In those on flibanserin it rose from 2.8 to 4.5 times a month while women receiving placebo reported also an increase of “satisfying sexual events” from 2.7 to 3.7 times a month. The onset of the flibanserin effect was seen from the first timepoint measured after 4 weeks of treatment and maintained throughout the treatment period.
The effectiveness of flibanserin was evaluated in three phase 3 clinical trials. Each of the three trials had two co-primary endpoints, one for satisfying sexual events (SSEs) and the other for sexual desire. Each of the 3 trials also had a secondary endpoint that measured distress related to sexual desire. All three trials showed that flibanserin produced an increase in the number of SSEs and reduced distress related to sexual desire. The first two trials used an electronic diary to measure sexual desire, and did not find an increase. These two trials also measured sexual desire using the Female Sexual Function index (FSFI) as a secondary endpoint, and an increase was observed using this latter measure.